

# Breast Disease-Oriented Team

---

Clinical Research Treatment Trial Flowchart



**NEOADJUVANT**

**ADJUVANT**

**NRG-BR008 (HER2+)**

Radiotherapy optimization

Coord: Stephany Ruiz

Accrual: 0/5

**UCI 21-185 (HER2+)**

HER2-targeting antibody drug conjugate

Coord: Juan Miranda

Accrual: 4/5

**A011801 (HER2+)**

Antibody drug conjugate +

kinase inhibitor

Coord: Stephany Ruiz

Accrual: 2/5

**UCI 22-111 (ER+/HER2-)**

Endocrine deprivation

Coord: Stephany Ruiz

Accrual: 0/5

**UCI 22-141 (TNBC)**

PDL-1 inhibitor

Coord: Stephany Ruiz

Accrual: 0/5

**NRG-BR007 (ER+/PR+/HER2-)**

Radiation therapy + Endocrine therapy

Coord: Juan Miranda/Stephany Ruiz

Accrual: 1/5



### 1L METASTATIC

### 2L METASTATIC

### 3L METASTATIC

**ETCTN 10546 (TNBC)**

Cytidine deaminase (CDA) inhibitor + nucleoside hypomethylating agent (HMA)  
 Coord: Alexis Chavez  
 Accrual: 1/5

**UCI 19-145 (HR+/HER2-)**

CDK 4/6 inhibitor+ER Regulator+Aromatase Inhibitor  
 Coord: Stephany Ruiz  
 Accrual: 9/20

**UCI 21-212 (TNBC)**

Antibody drug conjugate  
 Coord: Juan Miranda  
 Accrual: 0/3

**UCI 22-139 (HR+/HER2-)**

PI3K/mTOR inhibitor  
 Coord: Alexis Chavez  
 Accrual: 2/5

**UCI 22-222 (HR+/HER2-)**

PI3K inhibitor  
 Coord: Stephany Ruiz  
 Accrual: 0/4

**UCI 22-114 (ER+/HER2-)**

Proteasome-mediated degradation  
 Coord: Alexis Chavez  
 Accrual: 3/5



1L METASTATIC

2L METASTATIC

3L METASTATIC

UCI 22-09 (TNBC, HR+/HER2-)

Antibody drug conjugate  
Coord: Juan Miranda  
Accrual: 2/5

ETCTN 10302 (TNBC, HR+/HER2-)

Bone-targeted alpha particle  
emitting radiopharmaceutical  
Coord: Alexis Chavez  
Accrual: 5/10

S2007 (HER2-)

Antibody drug conjugate  
Coord: Alexis Chavez  
Accrual: 1/5

UCI 21-57 (HER2+, HER2 LOW)

IgG1-like antibody + CD47 inhibitor  
Coord: Alexis Chavez  
Accrual: 4/5

UCI 21-82 (TNBC, ER+/HER2-)

XBP1-splicing inhibitor  
Coord: Karla Kaminski  
Accrual: 1/5



■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

## 1L METASTATIC

### UCI 22-156 (HER2+)

Tumor infiltrating lymphocyte therapy

Coord: Juan Miranda

Accrual: 0/5

## 2L METASTATIC

## 3L METASTATIC

### ETCTN 10551 (germline BRCA 1/2+)

Hu5F9-G4 (magrolimab) recombinant humanized anti-CD47 mAb IgG4

Coord: Alexis Chavez

Accrual: 0/5



■ Open to Accrual   ■ Low Accruing   ■ Pending Activation/Suspended

## BASIC SCIENCE

UCI 18-136  
Coord: Billy Joel Sanchez/Caylee Carlton  
Accrual: 63/100

UCI 17-05 (BRCA1 -/-, +/+)  
Coord: Billy Joel Sanchez  
Accrual: 48/75